Smart cell delivery to target and control combination treatments for Alzheimer's
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures
A team is developing a living cell system to carry and release combinations of Alzheimer's medicines directly where they're needed for people with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Buck Institute for Research on Aging NIH-funded |
| Lab location | 1 site (Novato, United States) |
| Project ID | NIH-11126840 on NIH RePORTER |
What this research studies
Researchers are building living cells that can carry multiple Alzheimer's drugs, move to affected areas in the brain, and release medicine only when and where it's needed. The design aims to target three key problems in Alzheimer's—amyloid, tau, and harmful inflammation—while cutting down on side effects from giving many drugs at once. The work uses laboratory models to test whether this platform can protect antibodies and other drugs from causing toxicities when combined. If lab results are promising, the approach could move toward studies that involve people or donated patient samples.
Who could benefit from this research
Good fit: People with early-to-moderate Alzheimer's disease who are open to providing biological samples or taking part in future clinical studies would be the most likely candidates.
Not a fit: People without Alzheimer's or those with very advanced dementia unlikely to respond to disease-modifying treatments may not see direct benefit from this work.
Why it matters
Potential benefit: If successful, this could allow safer and more effective combination treatments for Alzheimer's by focusing drug action on diseased brain regions and lowering overall side effects.
How similar studies have performed: Some antibody drugs have reduced amyloid in early Alzheimer's but showed limited clinical benefit, and using cell-based targeted delivery for combination therapy is largely new and untested in humans.
Where this research is happening
Novato, United States
- Buck Institute for Research on Aging — Novato, United States (Active)
Researchers
- Principal investigator: Andersen, Julie Kay — Buck Institute for Research on Aging
- Study coordinator: Andersen, Julie Kay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.